About Event

Welcome to the Inaugural Genetic Vaccine Development for Infectious Diseases Summit

The 3-day case study-led program will bring together a wealth of knowledge into the complexities of the new and emerging field of gene-based vaccines, bringing together both pioneering academics and non-profit institutions, and leading biotech and pharma. Expect to hear updates on long-term clinical efficacy and safety, immune responses, novel delivery methods, and genetic platforms.  

Attend this event to:

22872 Genetic Vaccine Development for Infectious Diseases logo

Understand how the optimization of lipid nanoparticles allows for efficient and safe delivery of mRNA

Hear Moderna speak on the use of their mRNA technology platform for the development of mRNA-based vaccines, and a case study on mRNA-1273, one of the first approved COVID-19 vaccines

22872 Genetic Vaccine Development for Infectious Diseases logo

Learn the critical steps in mRNA vaccine development that allowed for the ‘lightspeed’ deployment of a SARS-CoV-2 vaccine

From pre-clinical studies to large-scale manufacture, BioNTech will be sharing how they went about developing the first COVID-19 vaccine, as well as sharing pre-clinical data on wider infectious disease programs

22872 Genetic Vaccine Development for Infectious Diseases logo

Optimizing next-generation vaccine development and lessons learned from COVID-19

Take part in an interactive panel discussion with Pfizer to learn how new vaccine technologies can stave off future outbreaks, and how the future of vaccine development has been changed by COVID-19

22872 Genetic Vaccine Development for Infectious Diseases logo

Discover the latest updates in DNA-based vaccines against infectious diseases

Hear INOVIO speak on efficacy in animal challenge models, thermo-stability of DNA vaccines, and clinical immunogenicity and safety profiling of INO-4800 in the race to be the first approved DNA vaccine for human use

22872 Genetic Vaccine Development for Infectious Diseases logo

Clinical and operational challenges of COVID-19 vaccine development and future opportunities

Understand how defining clinical trial endpoints for a new pathogen with limited pre-existing evidence can be overcome, why we need correlates of protection, and how to establish vaccine efficacy when placebo-controlled trials become more difficult